A Clinical Study to Investigate and Compare the Impact of High Protein Pasta, Lower Protein Pasta and White Rice on Blood Sugar Control in People With Type 1 Diabetes Mellitus (T1DM)

Not Applicable

Completed

• Conditions: Diabetes Mellitus, Type 1
• Interventions: Other: White rice; Other: Regular pasta; Other: High protein pasta

• Registration Number: NCT03362151
• Lead Sponsor: Sansum Diabetes Research Institute

Brief Summary

The aim of this clinical study is to investigate and compare the postprandial glycemic response to three different meal types rich in carbohydrates, that is, white pasta, high protein pasta and white rice consumed by individuals with T1DM.

Detailed Description

The aim of this clinical study is to investigate and compare the postprandial glycemic response to three different meal types rich in carbohydrates, that is, white pasta, high protein pasta and white rice consumed by individuals with T1DM and to demonstrate that:

1. The choice of carbohydrates consumed significantly affects the postprandial glycemic profile in people with type 1 diabetes and

2. The consumption of high protein pasta will present a tighter postprandial glycemic response.

Previous studies have evaluated the effect of white pasta and rice on postprandial glycemic response in people with type 1 diabetes. With this study, we aim to expand upon these findings by ensuring that the results can still be applied to more recent commercial food products (pasta, rice), but especially to evaluate the effect of high-protein pasta when compared to regularly consumed carbohydrates (white pasta, white rice).

After consuming the study meal, subjects will participate in an education session (a 2 hour class per each meal challenge session). Classes will be taught by a registered dietician and diabetes \& exercise expert and, as appropriate, a culinary instructor.

Study Timeline

• Study First Submitted: 2017-11-29
• Study First Submitted QC: 2017-11-29
• Study First Posted: 2017-12-05
• Study Start: 2018-01-01
• Primary Completion: 2018-08-02
• Study Completion: 2018-08-02
• Status Verified: 2018-09
• Last Update Submitted: 2018-09-04
• Last Update Posted: 2018-09-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

• Age ≥ 18 and ≤ 75 years at the time of screening.
• Clinical diagnosis of type 1 diabetes for at least one year.
• HbA1c ≤ 10%, as performed by point of care or central laboratory testing. A1c will be assessed at the screening visit, or if already completed within 2 months of the screening visit, the prior lab value may be used in lieu of repeating this assessment.
• Currently using insulin-to-carbohydrate ratio to calculate meal bolus sizes, and boluses for all meals and snacks that contain ≥ 5 grams of carbohydrate.
• Willing to refrain from taking acetaminophen products for the duration of the clinical trial. If acetaminophen is taken, subject is to avoid making any insulin dosing decisions based on CGM for at least 12 hours.
• For females, not currently known to be pregnant. If female and sexually active, must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative urine pregnancy test will be required for all premenopausal women who are not surgically sterile at the screening visit. Subjects who become pregnant will be discontinued from the study.
• Willing to abide by the study protocol and use study-provided devices.

Exclusion Criteria

• Gastrointestinal disease such as celiac disease or multiple food allergies.
• Any form of gluten sensitivity or wheat allergy.
• Allergies to any form of nuts and ingredients present in the study meals (tomatoes etc).
• History of gastroparesis.
• Pregnancy.
• Dermatological conditions that would preclude wearing a CGM sensor.
• Screening A1c > 10%.
• Any condition that could interfere with participating in the trial, based on the investigator's judgment.
• A recent injury to body or limb, muscular disorder, use of any medication, any carcinogenic disease, or other significant medical disorder if that injury, medication or disease in the judgment of the investigator will affect the completion of the protocol.
• Participation in another pharmaceutical or device trial at the time of enrollment or during the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
White rice	White rice	Subjects will bolus rapid acting insulin per their carbohydrate ratio just prior to a meal of white rice. They will consume this meal on two separate occasions.
Regular pasta	Regular pasta	Subjects will bolus rapid acting insulin per their carbohydrate ratio just prior to a meal of regular pasta. They will consume this meal on two separate occasions.
High protein pasta	High protein pasta	Subjects will bolus rapid acting insulin per their carbohydrate ratio just prior to a meal of high protein pasta. They will consume this meal on two separate occasions.

Primary Outcome Measures

Name	Time	Method
Delta glucose (maximum rise from baseline glucose) mg/dL	5 hours	Delta glucose (maximum rise from baseline glucose) from the start of the meal to the peak continuous glucose monitoring (CGM) glucose reading (mg/dL) during the 5-hour postprandial window, compared between the three meal types.

Secondary Outcome Measures

Name	Time	Method
Incremental area under the curve (area)	5 hours	Incremental area under the curve (iAUC) glucose level for the 5 hour postprandial period adjusted for baseline glucose at the start of the meal.
Time to peak glucose level (minutes)	5 hours	Time to peak glucose level (in minutes from intervention)
percent time glucose <70 mg/dL	5 hours	In case of postprandial hypoglycemia, percent time glucose \<70 mg/dL for the 5 hour postprandial period will be evaluated.

Trial Locations

Locations (1)

Sansum Diabetes Research Institute; 🇺🇸 Santa Barbara, California, United States